Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Platinum-Etoposide in 1L ES-SCLC (LUMINANCE)
NCT04774380Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2021
- Primary completion
- Jun 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 6
01
Overview
A Phase 3 trial of durvalumab in small cell lung cancer (SCLC), sponsored by AstraZeneca. Started Nov 2021; status: completed.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04774380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04774380.